"colorectal neoplasms; KRAS-BRAF; molecular targeted therapy; monoclonal antibodies"@en . "89337" . . . "P(ED1.1.00/02.0068), P(EE2.3.20.0045), Z(MSM0021622430)" . . "1" . "Dvo\u0159\u00E1kov\u00E1, Dana" . "Molekul\u00E1rn\u011B biologick\u00E1 diagnostika mutac\u00ED genu KRAS a BRAF u pacient\u016F s kolorekt\u00E1ln\u00EDm karcinomem - zku\u0161enosti laboratorn\u00EDho pracovi\u0161t\u011B" . "Posp\u00ED\u0161ilov\u00E1, \u0160\u00E1rka" . "Robe\u0161ov\u00E1, Blanka" . . . . "Hausnerov\u00E1, Jitka" . "Molecular Biological Diagnostics of KRAS and BRAF Mutations in Patients with Colorectal Cancer \u2013 Laboratory Experience"@en . . "Mayer, Ji\u0159\u00ED" . . "8"^^ . . . . "Bajerov\u00E1, Monika" . . "9"^^ . . . "Kyclov\u00E1, Jitka" . . "Ost\u0159\u00ED\u017Ekov\u00E1, Lenka" . . "Klinick\u00E1 onkologie" . . "Molekul\u00E1rn\u011B biologick\u00E1 diagnostika mutac\u00ED genu KRAS a BRAF u pacient\u016F s kolorekt\u00E1ln\u00EDm karcinomem - zku\u0161enosti laboratorn\u00EDho pracovi\u0161t\u011B"@cs . . "0862-495X" . . . . "CZ - \u010Cesk\u00E1 republika" . . "6"^^ . "RIV/00216224:14740/13:00068048" . . . "Background: Targeted biological therapy based on blocking growth factor receptors and inhibition of cancer-inducing signaling pathways is a new treatment facility for patients with colorectal cancer (CRC). Therapeutic agents are monoclonal antibodies targeting epidermal growth factor receptor (EGFR). Gene aberrations in the EGFR-induced pathways are negative predictors of therapeutic response. Determination of non-mutated KRAS is a requirement for the indication of targeted anti-EGFR therapy in the present time, BRAF mutation analysis is recommended. Comparison of our results with published data and verification of routine laboratory methods in relation to diagnostic kits were the purposes of this study. Patients and Methods: In addition to routine methods based on PCR, direct sequencing as well as two diagnostic kits for KRAS (codon 12 and 13) and BRAF (codon 600) mutation analysis were used for 132 patients."@en . "Va\u0161\u00EDkov\u00E1, Al\u017Eb\u011Bta" . "Molecular Biological Diagnostics of KRAS and BRAF Mutations in Patients with Colorectal Cancer \u2013 Laboratory Experience"@en . "14740" . "Molekul\u00E1rn\u011B biologick\u00E1 diagnostika mutac\u00ED genu KRAS a BRAF u pacient\u016F s kolorekt\u00E1ln\u00EDm karcinomem - zku\u0161enosti laboratorn\u00EDho pracovi\u0161t\u011B"@cs . . "V\u00FDchodiska: C\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba zalo\u017Een\u00E1 na blokov\u00E1n\u00ED receptor\u016F r\u016Fstov\u00FDch faktor\u016F a inhibici sign\u00E1ln\u00EDch drah navozuj\u00EDc\u00EDch n\u00E1dorov\u00E9 bujen\u00ED je novou terapeutickou mo\u017Enost\u00ED pro pacienty s kolorekt\u00E1ln\u00EDm karcinomem. Standardn\u00EDmi p\u0159\u00EDpravky t\u00E9to terapie jsou monoklon\u00E1ln\u00ED protil\u00E1tky zac\u00EDlen\u00E9 na receptor epiderm\u00E1ln\u00EDho r\u016Fstov\u00E9ho faktoru (EGFR). Negativn\u00EDm prediktorem l\u00E9\u010Debn\u00E9 odpov\u011Bdi jsou aberace v genech \u00FA\u010Dastn\u00EDc\u00EDch se sign\u00E1ln\u00EDch kask\u00E1d spou\u0161t\u011Bn\u00FDch EGFR. V sou\u010Dasn\u00E9 dob\u011B je podm\u00EDnkou pro indikaci c\u00EDlen\u00E9 anti-EGFR terapie pr\u016Fkaz nemutovan\u00E9ho genu KRAS, doporu\u010Dena je i muta\u010Dn\u00ED anal\u00FDza genu BRAF. C\u00EDlem pr\u00E1ce bylo srovnat v\u00FDsledky na\u0161eho pracovi\u0161t\u011B s publikovan\u00FDmi \u00FAdaji a ov\u011B\u0159it vyu\u017Eitelnost standardn\u00EDch laboratorn\u00EDch metod ve srovn\u00E1n\u00ED s diagnostick\u00FDmi soupravami. Soubor pacient\u016F a metody: Pro anal\u00FDzu KRAS (kodon 12 a 13) a BRAF (kodon 600) u 132 pacient\u016F byly pou\u017Eity standardn\u00ED metody na principu PCR a p\u0159\u00EDm\u00E9 sekvenace a dv\u011B diagnostick\u00E9 soupravy."@cs . "http://www.linkos.cz/files/klinicka-onkologie/176/4184.pdf" . . . "RIV/00216224:14740/13:00068048!RIV14-MSM-14740___" . "26" . "Molekul\u00E1rn\u011B biologick\u00E1 diagnostika mutac\u00ED genu KRAS a BRAF u pacient\u016F s kolorekt\u00E1ln\u00EDm karcinomem - zku\u0161enosti laboratorn\u00EDho pracovi\u0161t\u011B" . "[3F5CF4D1CF08]" . "V\u00FDchodiska: C\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba zalo\u017Een\u00E1 na blokov\u00E1n\u00ED receptor\u016F r\u016Fstov\u00FDch faktor\u016F a inhibici sign\u00E1ln\u00EDch drah navozuj\u00EDc\u00EDch n\u00E1dorov\u00E9 bujen\u00ED je novou terapeutickou mo\u017Enost\u00ED pro pacienty s kolorekt\u00E1ln\u00EDm karcinomem. Standardn\u00EDmi p\u0159\u00EDpravky t\u00E9to terapie jsou monoklon\u00E1ln\u00ED protil\u00E1tky zac\u00EDlen\u00E9 na receptor epiderm\u00E1ln\u00EDho r\u016Fstov\u00E9ho faktoru (EGFR). Negativn\u00EDm prediktorem l\u00E9\u010Debn\u00E9 odpov\u011Bdi jsou aberace v genech \u00FA\u010Dastn\u00EDc\u00EDch se sign\u00E1ln\u00EDch kask\u00E1d spou\u0161t\u011Bn\u00FDch EGFR. V sou\u010Dasn\u00E9 dob\u011B je podm\u00EDnkou pro indikaci c\u00EDlen\u00E9 anti-EGFR terapie pr\u016Fkaz nemutovan\u00E9ho genu KRAS, doporu\u010Dena je i muta\u010Dn\u00ED anal\u00FDza genu BRAF. C\u00EDlem pr\u00E1ce bylo srovnat v\u00FDsledky na\u0161eho pracovi\u0161t\u011B s publikovan\u00FDmi \u00FAdaji a ov\u011B\u0159it vyu\u017Eitelnost standardn\u00EDch laboratorn\u00EDch metod ve srovn\u00E1n\u00ED s diagnostick\u00FDmi soupravami. Soubor pacient\u016F a metody: Pro anal\u00FDzu KRAS (kodon 12 a 13) a BRAF (kodon 600) u 132 pacient\u016F byly pou\u017Eity standardn\u00ED metody na principu PCR a p\u0159\u00EDm\u00E9 sekvenace a dv\u011B diagnostick\u00E9 soupravy." .